Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure | Zendy

Deanna J. Buehrle | Zendy; Ryan K. Shields | Zendy; Lloyd Clarke | Zendy; Brian A. Potoski | Zendy; Cornelius J. Clancy | Zendy; M. Hong Nguyen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure

Author(s) -

Deanna J. Buehrle,

Ryan K. Shields,

Lloyd Clarke,

Brian A. Potoski,

Cornelius J. Clancy,

M. Hong Nguyen

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01243-16

Subject(s) - bacteremia , pseudomonas aeruginosa , medicine , antimicrobial , drug resistance , carbapenem , antibiotics , antibacterial agent , microbiology and biotechnology , bacteria , biology , genetics

We reviewed 37 patients treated for bacteremia due to carbapenem-resistant (CR)Pseudomonas aeruginosa . Although 65% of isolates were multiple-drug resistant, therapeutic options were available, as all were susceptible to ≥1 antibiotic. A total of 92% of patients received active antimicrobial therapy, but only 57% received early active therapy (within 48 h). Fourteen-day mortality was 19%. Microbiologic failure occurred in 29%. The Pitt bacteremia score (P = 0.046) and delayed active therapy (P = 0.027) were predictive of death and microbiologic failure, respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research